Dorsomorphin, compound C is a cell-permeable pyrrazolopyrimidine derivative that inhibits AMP kinase in an ATP-competitive manner. Dorsomorphin displays no significant inhibition of ZAPK, SYKK, PKCT, PKA and JAK3. Dorsomorphin decreases food intake in mice and inhibits the effects of AICAR and metformin. Dorsomorphin has been shown to inhibit BMP type I receptors ALK2, ALK3 and ALK6.
Bone morphogenetic protein (BMP) are members of the transforming growth factor-β (TGF-β) superfamily determining embryonic patterning and tissue morphogenesis. The recent discovery of dorsomorphin, the first chemical inhibitor of BMP receptor signaling bone disease provides hope for future fibrodysplasia ossificans progressiva (FOP) therapies.